Blog
RSS FeedPosted by Michael Wonder on 25 Jul 2023
Gilead Sciences announces its largest commitment to health equity for Australian and Canadian indigenous communities
23 July 2023 - $6 million USD in funding will help address health disparities among indigenous communities with a focus ...
Posted by Michael Wonder on 25 Jul 2023
Health Canada approves AbbVie's Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis
25 July 2023 - Approval is based on results from three Phase 3 studies: two for induction and one for maintenance. ...
Posted by Michael Wonder on 23 Jul 2023
Health Canada approves Trodelvy (sacituzumab govitecan) in pre-treated HR+/HER2- metastatic breast cancer
20 July 2023 - Trodelvy has now improved survival in both pre-treated HR+/HER2- metastatic breast cancer and in second-line metastatic ...
Posted by Michael Wonder on 20 Jul 2023
Changes to CADTH’s rapid response service
20 July 2023 - As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products ...
Posted by Michael Wonder on 14 Jul 2023
Health Canada approves Lynparza in combination with abiraterone and prednisone or prednisolone for patients with BRCA mutated metastatic castration-resistant prostate cancer
13 July 2023 - Conditional approval based on data from Phase 3 PROpel trial. ...
Posted by Michael Wonder on 13 Jul 2023
Slynd (drospirenone) is now covered by the Régie de l’assurance maladie du Québec
12 July 2023 - Duchesnay is pleased to announce that Slynd (drospirenone 4 mg), used to prevent pregnancy in girls ...
Posted by Michael Wonder on 12 Jul 2023
Lupin Announces Health Canada approval of tiotropium bromide inhalation powder for treatment of COPD
11 July 2023 - Lupin announced that on 26 May 2023, its Canada subsidiary, Lupin Pharma Canada received approval from ...
Posted by Michael Wonder on 12 Jul 2023
Ruzurgi is now available and covered by the vast majority of public health and private insurance plans
11 July 2023 - Médunik Canada is pleased to announce that Ruzurgi (amifampridine) is now covered by the vast majority of ...
Posted by Michael Wonder on 06 Jul 2023
Dexcom G7 receives Health Canada approval: next generation continuous glucose monitoring system with unmatched accuracy coming to Canadians
4 July 2023 - Dexcom announced today that Health Canada has approved the next generation Dexcom G7 Continuous Glucose Monitoring System ...
Posted by Michael Wonder on 30 Jun 2023
Moderna initiates rolling submission to Health Canada for updated COVID-19 vaccine
29 June 2023 - Health Canada submission follows international recommendations to develop monovalent XBB.1.5 COVID-19 vaccines. ...
Posted by Michael Wonder on 30 Jun 2023
Endo announces approval of Xcopri (cenobamate tablets) in Canada
29 June 2023 - Endo International announced today that Paladin Labs, an Endo operating company, received Health Canada's approval of ...
Posted by Michael Wonder on 29 Jun 2023
Ontario to publicly reimburse Albrioza for the treatment of ALS
28 June 2023 - Ontario lists Albrioza on its drug benefit formulary, becoming the first province to publicly reimburse Albrioza, ...
Posted by Michael Wonder on 27 Jun 2023
Sun Pharma announces Health Canada approval of Absorica LD (isotretinoin capsules) for treatment of severe nodular acne
26 June 2023 - A new formulation of isotretinoin, the first in over a decade and the only micronised formulation ...
Posted by Michael Wonder on 21 Jun 2023
Imbruvica is included in the high-cost protection with a changed benefit limitation
19 June 2023 - Ibrutinib (Imbruvica)140 mg, 280 mg & 420 mg tablets are now subsidised for the treatment ...
Posted by Michael Wonder on 20 Jun 2023
FDA launches pilot program to help reduce risks associated with using laboratory developed tests to identify cancer biomarkers
20 June 2023 - Pilot geared toward sponsors of certain oncology drug products used with certainin vitro diagnostic tests ...